ATE383430T1 - Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren - Google Patents
Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumorenInfo
- Publication number
- ATE383430T1 ATE383430T1 AT98912977T AT98912977T ATE383430T1 AT E383430 T1 ATE383430 T1 AT E383430T1 AT 98912977 T AT98912977 T AT 98912977T AT 98912977 T AT98912977 T AT 98912977T AT E383430 T1 ATE383430 T1 AT E383430T1
- Authority
- AT
- Austria
- Prior art keywords
- tumors
- recombinant antibodies
- bearing cells
- immune conjugates
- conjugates targeted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4143797P | 1997-03-20 | 1997-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE383430T1 true ATE383430T1 (de) | 2008-01-15 |
Family
ID=21916511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98912977T ATE383430T1 (de) | 1997-03-20 | 1998-03-19 | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7541034B1 (de) |
| EP (1) | EP0970227B1 (de) |
| JP (3) | JP2002501488A (de) |
| AT (1) | ATE383430T1 (de) |
| AU (1) | AU740904B2 (de) |
| CA (1) | CA2284665C (de) |
| DE (1) | DE69838979T2 (de) |
| ES (1) | ES2300122T3 (de) |
| WO (1) | WO1998041641A1 (de) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395276B1 (en) | 1997-05-02 | 2002-05-28 | Immunomedics, Inc. | Immunotoxins directed against malignant cells |
| CA2284665C (en) | 1997-03-20 | 2010-08-17 | David Fitzgerald | Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| AU2001268363B2 (en) | 2000-06-20 | 2006-08-17 | Biogen Idec Inc. | Treatment of B cell associated diseases |
| ATE391174T1 (de) | 2000-10-20 | 2008-04-15 | Chugai Pharmaceutical Co Ltd | Modifizierter tpo-agonisten antikörper |
| US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| CA2461351C (en) * | 2001-09-26 | 2014-08-05 | Ira H. Pastan | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
| DK1507556T3 (en) | 2002-05-02 | 2016-09-12 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
| GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
| AU2004293471C1 (en) | 2003-11-25 | 2011-02-24 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-CD22 antibodies and immunoconjugates |
| EP1870458B1 (de) | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2-STRUKTURISOMERE |
| EP1870459B1 (de) | 2005-03-31 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur polypeptidherstellung mit regulation des zusammenbaus |
| US8071559B2 (en) | 2005-05-02 | 2011-12-06 | Cold Spring Harbor Laboratory | Compositions and methods for cancer diagnosis and treatment |
| CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
| CA2610987C (en) | 2005-06-10 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| EA015992B1 (ru) * | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
| WO2009124109A1 (en) | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
| US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| US8936792B2 (en) | 2009-09-11 | 2015-01-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with reduced immunogenicity |
| CN103079666B (zh) | 2010-07-30 | 2017-10-24 | 米迪缪尼有限公司 | 纯化活性多肽或免疫偶联物的方法 |
| AU2012205301B2 (en) | 2011-01-14 | 2017-01-05 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| BR112013031262A2 (pt) | 2011-06-09 | 2016-11-22 | Us Health | "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica". |
| US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
| EP2755993B1 (de) | 2011-09-16 | 2017-11-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen |
| CN109485730A (zh) | 2011-10-20 | 2019-03-19 | 美国卫生和人力服务部 | 抗cd22嵌合抗原受体 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| IN2015DN00552A (de) | 2012-07-19 | 2015-06-26 | Redwood Bioscience Inc | |
| JP6553515B2 (ja) | 2012-12-20 | 2019-07-31 | メディミューン，エルエルシー | 免疫複合体の製造方法 |
| US9890369B2 (en) | 2013-06-20 | 2018-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor |
| CA2925256C (en) | 2013-09-27 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| AU2014329437B2 (en) | 2013-10-06 | 2018-10-18 | F. Hoffmann-La Roche Ag | Modified Pseudomonas exotoxin A |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| US10441649B2 (en) | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| LT3303373T (lt) | 2015-05-30 | 2020-07-10 | Molecular Templates, Inc. | Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| AU2016354009B2 (en) | 2015-11-09 | 2021-05-20 | R.P. Scherer Technologies, Llc | Anti-CD22 antibody-maytansine conjugates and methods of use thereof |
| CN112807429A (zh) | 2015-11-19 | 2021-05-18 | 雷维托普有限公司 | 用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用 |
| EP3398965A4 (de) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur förderung der effizienz der reinigung von polypeptid mit fc-region |
| US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| WO2019055955A1 (en) | 2017-09-18 | 2019-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN |
| US20230212286A1 (en) | 2020-06-01 | 2023-07-06 | Innobation Bio Co., Ltd. | Antibodies specific for cd22 and uses thereof |
| IL298921A (en) | 2020-07-10 | 2023-02-01 | Hoffmann La Roche | Antibodies that bind to cancer cells and direct radionuclides to said cells |
| US20230372522A1 (en) * | 2020-09-29 | 2023-11-23 | Kunming Sinoway Natural Pharmaceuticals Co., Ltd. | Humanized anti-cd22 recombinant immunotoxin and application thereof |
| KR102393776B1 (ko) | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| AU2021412988A1 (en) | 2020-12-31 | 2023-06-15 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
| CA3204161A1 (en) | 2021-01-11 | 2022-07-14 | Jagesh Vijaykumar SHAH | Use of cd8-targeted viral vectors |
| KR20230131205A (ko) | 2021-01-13 | 2023-09-12 | 에프. 호프만-라 로슈 아게 | 병용 요법 |
| EP4314049A1 (de) | 2021-03-25 | 2024-02-07 | Dynamicure Biotechnology LLC | Anti-igfbp7-konstrukte und verwendungen davon |
| IL308637A (en) | 2021-05-19 | 2024-01-01 | Sana Biotechnology Inc | Primary hypoimmunogenic T cells are RHD negative |
| KR20240013135A (ko) | 2021-05-27 | 2024-01-30 | 사나 바이오테크놀로지, 인크. | 조작된 hla-e 또는 hla-g를 포함하는 저면역원성 세포 |
| EP4370544A2 (de) | 2021-07-14 | 2024-05-22 | Sana Biotechnology, Inc. | Veränderte expression von y-chromosom-gebundenen antigenen in hypoimmunogenen zellen |
| JP2024528981A (ja) | 2021-08-04 | 2024-08-01 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ４標的化ウイルスベクターの使用 |
| JP2024534772A (ja) | 2021-08-11 | 2024-09-26 | サナ バイオテクノロジー，インコーポレイテッド | 同種異系細胞療法用の遺伝子改変細胞 |
| AU2022325232A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| MX2024001443A (es) | 2021-08-11 | 2024-05-15 | Sana Biotechnology Inc | Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas. |
| WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| EP4448549A2 (de) | 2021-12-17 | 2024-10-23 | Sana Biotechnology, Inc. | Modifizierte paramyxoviridae-fusionsglycoproteine |
| KR20240137574A (ko) | 2021-12-23 | 2024-09-20 | 사나 바이오테크놀로지, 인크. | 자가면역 질환 치료를 위한 키메라 항원 수용체[chimeric antigen receptor, car] t 세포 및 관련 방법 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| AU2023220128A1 (en) | 2022-02-17 | 2024-08-22 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024097311A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Hypoimmunogenic mail cells, methods of making and methods of using same |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56145222A (en) * | 1980-04-28 | 1981-11-11 | Toshiyuki Hamaoka | Improved antibody and its preparation |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US5476659A (en) | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US5045451A (en) | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
| US5165923A (en) | 1989-11-20 | 1992-11-24 | Imperial Cancer Research Technology | Methods and compositions for the treatment of hodgkin's disease |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5591629A (en) * | 1994-04-29 | 1997-01-07 | Mayo Foundation For Medical Education & Research | Monoclonal antibodies which promote central nervous system remyelination |
| CA2284665C (en) * | 1997-03-20 | 2010-08-17 | David Fitzgerald | Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors |
-
1998
- 1998-03-19 CA CA2284665A patent/CA2284665C/en not_active Expired - Lifetime
- 1998-03-19 AT AT98912977T patent/ATE383430T1/de active
- 1998-03-19 US US09/381,497 patent/US7541034B1/en not_active Expired - Fee Related
- 1998-03-19 JP JP54081298A patent/JP2002501488A/ja not_active Withdrawn
- 1998-03-19 DE DE69838979T patent/DE69838979T2/de not_active Expired - Lifetime
- 1998-03-19 WO PCT/US1998/005453 patent/WO1998041641A1/en active IP Right Grant
- 1998-03-19 AU AU67646/98A patent/AU740904B2/en not_active Expired
- 1998-03-19 EP EP98912977A patent/EP0970227B1/de not_active Expired - Lifetime
- 1998-03-19 ES ES98912977T patent/ES2300122T3/es not_active Expired - Lifetime
-
2008
- 2008-03-18 JP JP2008070484A patent/JP2008208131A/ja active Pending
-
2009
- 2009-04-30 US US12/433,737 patent/US9592304B2/en not_active Expired - Fee Related
-
2010
- 2010-03-31 JP JP2010084519A patent/JP2010200752A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2284665C (en) | 2010-08-17 |
| AU6764698A (en) | 1998-10-12 |
| JP2002501488A (ja) | 2002-01-15 |
| WO1998041641A1 (en) | 1998-09-24 |
| CA2284665A1 (en) | 1998-09-24 |
| JP2008208131A (ja) | 2008-09-11 |
| AU740904B2 (en) | 2001-11-15 |
| EP0970227B1 (de) | 2008-01-09 |
| JP2010200752A (ja) | 2010-09-16 |
| DE69838979T2 (de) | 2008-12-24 |
| ES2300122T3 (es) | 2008-06-01 |
| EP0970227A1 (de) | 2000-01-12 |
| US7541034B1 (en) | 2009-06-02 |
| US20090305411A1 (en) | 2009-12-10 |
| DE69838979D1 (de) | 2008-02-21 |
| US9592304B2 (en) | 2017-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| ATE365562T1 (de) | Zielgerichtete kombinations-immuntherapie für krebs | |
| CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
| ATE296105T1 (de) | Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel | |
| DE69939820D1 (de) | Internalisierende erbb2 antikörper | |
| TR200003161T2 (tr) | Poliol-IFN-Beta konjugatları | |
| BR0209254A (pt) | anticorpos de bloqueio cripto e usos dos mesmos | |
| EA200301159A1 (ru) | Цитотоксические иммуноконъюгаты антитела к cd44 | |
| BRPI0012196B8 (pt) | artigo industrializado | |
| DK1180123T3 (da) | Immunkonjugater, der har höj bindingsaffinitet | |
| ATE470714T1 (de) | Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen | |
| ATE463505T1 (de) | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| DE602004031714D1 (de) | Anthracyclin-anti-cd74-antikörperkonjugate | |
| NZ334828A (en) | Contains no O-acetyl groups detectable by NMR and binds to antibodies to S.aureus further conjugated with Pseudomonas aeruginosa exotoxin A as an immunocarrier to detect S.aureus infection | |
| IL135775A0 (en) | Antibodies and immunoconjugates having high binding affinity for mesothelin | |
| ATE527358T1 (de) | Ribosomen inaktivierendes protein vom typ-1 | |
| ATE331728T1 (de) | Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie | |
| DK0845998T3 (da) | Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles | |
| ES2113376T3 (es) | Conjugados de anticuerpos para tratamiento de enfermedades neoplasticas. | |
| RU92016354A (ru) | Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата | |
| PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
| ATE249243T1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat | |
| ATE331730T1 (de) | Neue depsipeptid-verbindung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0970227 Country of ref document: EP |